gfp927z Tuesday, 02/23/21 08:31:53 PM Re: ombowstring post# 18714 Post # of 18748 Ombow, Just curious if you are still in CYDY? In addition to the company sitting on the trial results, looking at the recent press release the emphasis is clearly being shifted away from Covid and onto their other programs, HIV, cancer, etc. That shift is really obvious, and they are lowering expectations for Covid. I've seen this type spin before in bio press releases. The idea that a company can just sit on clinical data almost indefinitely is something I've never seen before with a small bio. Large companies can bury disappointing trial results, but a small company can't legally do that since they often only have one lead drug and the company's future is riding on it. So key clinical data is a material event that must be disclosed to shareholders. At least that's the way it always was when I was following bio companies, which admittedly was a few years back. But this weasel CEO seems to think he can just sit on key data, put it off week after week. The company's silence has been a huge red flag. They delayed the mild/mod trial data release also, but not this long. With good clear positive data, the press release announcement usually comes quickly. I wouldn't trust that CEO even a little, zip.